Journal of Research in Clinical Oncology https://jrco.info/index.php/journal <p><strong>Journal of Research in Clinical Oncology</strong>, ISSN 2770-1875, is an international, multidisciplinary and open-access journal which publishes clinical research studies in oncology and relative areas. The journal aims to present scientific viewpoints on innovative approaches and effective practice from the whole world community. It especially encourages the researches helpful to cancer patients in developing areas. It mainly works for submission of manuscripts with the topic of oncology covering diagnosis, treatment, epidemiology, genetis and pathology etc. It offers fast publication schedule and all the research articles published are peer-reviewed. Journal of Research in Clinical Oncology is issued every two months online.</p> en-US editor@jrco.info (Joe Stephens) zhengxin@jrco.info (Xin Zheng) Wed, 22 Sep 2021 11:00:18 +0000 OJS 3.3.0.7 http://blogs.law.harvard.edu/tech/rss 60 Hyperthermia: A Cancer Treatment Approach Worth More Attention https://jrco.info/index.php/journal/article/view/2 <div class="page" title="Page 1"> <div class="layoutArea"> <div class="column"> <p>Hyperthermia is often combined with radiation therapy and chemotherapy in cancer treatment. It can also assist in cancer immunotherapy. Considering the minor side effect on normal tissues, hyperthermia could be applied repeatedly. More attention is necessary to incorporate hyperthermia in clinical cancer workflows.</p> </div> </div> </div> Yingjuan Zheng, Yunkeli Lin, Daoke Yang Copyright (c) 2021 Journal of Research in Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0 https://jrco.info/index.php/journal/article/view/2 Thu, 23 Sep 2021 00:00:00 +0000 Clinical Study of Combination of Deep Microwave Hyperthermia and Regional Infusion Chemotherapy for Advanced Pancreatic Cancer https://jrco.info/index.php/journal/article/view/5 <p><strong>Objective</strong>: Investigate the efficacy of deep hyperthermia combined with regional infusion chemotherapy for advanced pancreatic cancer and its influence on the&nbsp;improvement of&nbsp;KPS&nbsp;score.&nbsp;</p> <p><strong>Methods</strong>:&nbsp;Data 90&nbsp;patients with advanced pancreatic cancer treated in&nbsp;Henan Provicial Hospital were&nbsp;retrospectively analyzed. According to different treatment methods, the patients were divided into the observation group (n=45) and the control group (n=45). The observation group received peripheral chemotherapeutic drug perfusion&nbsp;plus deep microwave hyperthermia, while the control group only received peripheral chemotherapeutic drug perfusion.&nbsp;The short-term efficacy, disease control, survival, and&nbsp;KPS&nbsp;score were compared between the groups.</p> <p><strong>Results</strong>:&nbsp;Both groups of patients successfully completed the treatment according to the design plan. After treatment, the total effective tumor control in the observation group was&nbsp;75.56%; the control rate of ascites was&nbsp;92.86%; the control rate of abdominal pain and bloating was&nbsp;85.71%; the&nbsp;KPS&nbsp;score increased by more than&nbsp;15&nbsp;points was&nbsp;62.22%; the one-year survival period was&nbsp;66.66% and the two-year survival period was&nbsp;20%, which is significantly higher than&nbsp;37.78%,&nbsp;64.29%,&nbsp;47.06%,&nbsp;37.78% in control group that had the one-year survival period&nbsp;37.78% and the 2-&nbsp;year survival period&nbsp;8.89%. The differences were statistically significant (P&lt;0.05).&nbsp;There was no significant difference in adverse reactions caused by treatment between the&nbsp;two&nbsp;groups.&nbsp;</p> <p><strong>Conclusion</strong>:&nbsp;The combination of deep microwave hyperthermia and regional infusion chemotherapy had a significant clinical effect in the treatment of advanced pancreatic cancer. It effectively improved the short-term curative effect, clinical symptoms, and quality of life of patients, which also prolonged survival without serious adverse reactions, and was worthy of clinical application.</p> Zongzhi Liang, Junfang Pang, Yapeng Huang, Bin Li, Shengnan Hu, Huizhen Zhang Copyright (c) 2021 Journal of Research in Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0 https://jrco.info/index.php/journal/article/view/5 Thu, 23 Sep 2021 00:00:00 +0000 Comparative Study on the Effect of Intraperitoneal Hyperthermia Chemotherapy on Cancerous Ascites of Different Temperatures https://jrco.info/index.php/journal/article/view/3 <p><strong>Objective</strong>: The&nbsp;difference of curative effects of&nbsp;intraperitoneal hyperthermia chemotherapy in the treatment of cancerous ascites with different action temperatures was studied.&nbsp;</p> <p><strong>Methods</strong>: 200 cases of patients with malignant ascites from our hospital that treated with the intraperitoneal hyperthermia chemotherapy during 2004 to 2020 were selected, among which 100 cases in observation group had hyperthermia temperature of 43℃ and 100 cases in control group had hyperthermia temperature of 42℃. The short/long-term curative effects, half-year and one-year survival period, and post-treatment complications of the two groups of patients were compared and analyzed.&nbsp;</p> <p><strong>Results</strong>: The total efficacy of 43℃ intraperitoneal hyperthermia chemotherapy group of patients was 91%, and the total efficacy of control group 42℃ was 62%. The half-year survival of 43℃ observation group was 96%, and one-year survival was 87%; while the half-year survival of control group was 66%, and one-year survival was 51%. <strong>Conclusion</strong>: the clinical treatment efficacy of patients treated with 43℃ intraperitoneal hyperthermia chemotherapy was notably better than the patients treated with 42℃ intraperitoneal hyperthermia chemotherapy. &nbsp;There was&nbsp;statistical difference&nbsp;in the adverse reactions&nbsp;between the&nbsp;two groups of patients after treatment.</p> Zongzhi Liang, Yapeng Huang, Junfang Pang, Bin Li, Jingna Wang, Shengnan Hu, Huizhen Zhang Copyright (c) 2021 Journal of Research in Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0 https://jrco.info/index.php/journal/article/view/3 Thu, 23 Sep 2021 00:00:00 +0000 Comparative Study on the Effect of 42 ℃ Intraperitoneal Hyperthermia Chemotherapy on Cancerous Ascites with Different Treatment Time https://jrco.info/index.php/journal/article/view/4 <p><strong>Objective</strong>: The&nbsp;difference of curative effects of&nbsp;42&nbsp;℃&nbsp;intraperitoneal hyperthermia chemotherapy in the treatment of cancerous ascites with different treatment time was studied to find out the best matching treatment time of hyperthermia chemotherapy.&nbsp;</p> <p><strong>Methods</strong>: 200 cases of patients with malignant ascites from our hospital that treated with the heat intraperitoneal chemotherapy during 2004 to 2020 were selected, among which 100 cases had hyperthermia time of 60 minutes and 100 cases had hyperthermia time of 120 minutes. The curative effects, half-year and one-year survival period, and post-treatment complications of the two groups of patients were compared and analyzed.&nbsp;</p> <p><strong>Results</strong>: The&nbsp;treatment efficiency, half-year survival and one-year survival period of the patients in the 120 minutes treatment&nbsp;group&nbsp;were significantly better than those in the&nbsp;60 minutes treatment group. The data comparison and analysis showed&nbsp;statistical differences.&nbsp;However, there was no&nbsp;statistical difference&nbsp;in the adverse reactions&nbsp;between the&nbsp;two groups of patients after treatment.</p> Zongzhi Liang, Yapeng Huang, Junfang Pang, Bin Li, Shengnan Zhang, Huizhen Zhang Copyright (c) 2021 Journal of Research in Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0 https://jrco.info/index.php/journal/article/view/4 Thu, 23 Sep 2021 00:00:00 +0000 An Approach to Study Prognosis of Bacille Calmette-Gu ́erin for Bladder Cancer Treatment https://jrco.info/index.php/journal/article/view/1 <div class="page" title="Page 1"> <div class="layoutArea"> <div class="column"> <p>Bladder cancer is a common cancer in the world. One treatment approach, Bacille Calmette Gu ́erin (BCG), has been used for more than 30 years. There is no prognosis biomarker for BCG treatment. Here we used public data to screen candidate genes as biomarkers for BCG prognosis, presenting the dry-lab way for scientific study which is cost-effective especially for researchers with limited resources. The candidates need further verification on its potential. Sensitive prognosis markers would help more precisive BCG application, which may promote BCG application where it is still limited.</p> </div> </div> </div> Suna Zhai, Xiufang Lv, Bingyan Li, Pengcheng Zhou, Tiansong Liang Copyright (c) 2021 Journal of Research in Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0 https://jrco.info/index.php/journal/article/view/1 Thu, 23 Sep 2021 00:00:00 +0000